Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic
J Ryan Bariola, Erin K McCreary, Tina Khadem, Graham M. Snyder, Richard J. Wadas, David A. Nace, Douglas B. White, Donald M. Yealy, Mark Schmidhofer
Abstract
Emergency authorized coronavirus disease 2019 (COVID-19)-neutralizing monoclonal antibodies can aid outpatients with mild to moderate COVID-19 infection. Many report barriers to adequate distribution and uptake. We present our model for distribution in a large health system as well as early lessons learned.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)MedicinePandemicMonoclonal antibody2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirusDistribution (mathematics)AntibodyDiseaseInfectious disease (medical specialty)ImmunologyOutbreakInternal medicineMathematicsMathematical analysisSARS-CoV-2 and COVID-19 ResearchInhalation and Respiratory Drug DeliveryDiabetes and associated disorders